my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
01-05-2007: UCB announces that it has received tenders amounting to 87.62% of the total outstanding share capital of SCHWARZ PHARMA AG (or 86.80% of the fully diluted share capital, including treasury shares) during its tender offer for SCHWARZ PHARMA which closed on December 28, 2006 at midnight. Shareholders of SCHWARZ PHARMA, who have tendered their shares during the final acceptance period, are expected to receive, on January 11, 2007, payment of 50 euros in cash and 0.8735 new UCB shares as consideration for each tendered SCHWARZ PHARMA share. The listing of these new UCB shares on Eurolist by Euronext Brussels is expected to occur on January 8, 2007.
Watchlist
This is where you can add this news to your personal favourites
Successful takevoer of Schwarz Pharma by UCB
UCB announces that it has received tenders amounting to 87.62% of the total outstanding share capital of SCHWARZ PHARMA AG (or 86.80% of the fully diluted share capital, including treasury shares) during its tender offer for SCHWARZ PHARMA which closed on December 28, 2006 at midnight. Shar ... more
New CEO of SCHWARZ PHARMA joins executive commitee of UCB
UCB appointed Detlef Thielgen, SCHWARZ PHARMA's new Chief Executive Officer, to UCB's Executive Committee effective January 1, 2007. In his career with SCHWARZ PHARMA AG, Detlef Thielgen has held several positions in finance and controlling, including Chief Financial Officer in the USA (19 ... more
Significant acceptances by SCHWARZ shareholders for UCB tender offer
The final total of acceptances received by midnight on Friday December 8 will be available on Thursday December 14, 2006. Acceptances already counted show UCB has received tenders in excess of 76% of the fully diluted share capital of SCHWARZ PHARMA. As is required in such a transaction in ... more
UCB transfers UK-based medicinal chemistry program to BioFocus DPI
Galapagos NV announced that its service division BioFocus DPI and UCB have signed a contract for the provision of chemistry services in the UK by BioFocus DPI, for one of UCB's medicinal chemistry programs. The total contract value for Galapagos could potentially exceed EUR4 M. Additionally ... more
Pierre Fabre acquires Over-The-Counter Business of UCB in France, Benelux, Switzerland and Greece
Pierre Fabre and UCB jointly announce that Pierre Fabre has acquired the OTC business of UCB in France, Benelux, Switzerland and Greece. The acquisition involves certain mature products with strong brand names (a.o. Carbolevure, Revitalose, Balsoclase, Toclase), representing sales of approx ... more
Successful takevoer of Schwarz Pharma by UCB
UCB announces that it has received tenders amounting to 87.62% of the total outstanding share capital of SCHWARZ PHARMA AG (or 86.80% of the fully diluted share capital, including treasury shares) during its tender offer for SCHWARZ PHARMA which closed on December 28, 2006 at midnight. Shar ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
